Abstract
Psoriasis is a prevalent chronic inflammatory skin disease of unknown etiology. Recent advances in understanding the pathogenesis of psoriasis suggest that IL-17 is a key proinflammatory mediator present in the skin. Several agents targeting IL-17 or its receptor are in clinical trials for the treatment of psoriasis. This review focuses on the biological rationale and the results of clinical trials with ixekizumab, a humanized IgG4 monoclonal antibody. Ixekizumab binds the IL-17A homodimer, thereby blocking the binding of IL-17A to the IL-17 receptor. The currently available Phase I-III data indicate that ixekizumab is a promising drug, although long-term data of efficacy and safety are needed before ixekizumab and other IL-17 targeting therapeutics can find their place in clinical practice.
| Original language | English |
|---|---|
| Journal | Expert Review of Clinical Immunology |
| Volume | 11 |
| Issue number | 4 |
| Pages (from-to) | 435-42 |
| Number of pages | 8 |
| ISSN | 1744-666X |
| DOIs | |
| Publication status | Published - 1 Apr 2015 |
Keywords
- Animals
- Antibodies, Monoclonal, Humanized
- Clinical Trials as Topic
- Humans
- Interleukin-17
- Molecular Targeted Therapy
- Protein Binding
- Psoriasis
- Receptors, Interleukin-17
- Skin